45 results about "Adrenocortical hormone" patented technology

Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2α, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules. This resulted in the identification of negative allosteric modulators (NAMs) of the CRFBP(10 kD)-CRF2 complex that blunt CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons in the ventral tegmental area (VTA). These results provide the first evidence of specific roles for CRF2 and CRFBP in the modulation of neuronal activity and suggest that NMDARs in the VTA may be a target for the treatment of stress and substance abuse disorders such as alcohol use disorder.

A method of affecting sleep and sleep-related behaviors of a mammal having a diurnal rhythm, by reducing the basal activity of the hypothalamus-pituitary-adrenal axis by administering an effective amount of a sensory regimen is disclosed. Such reduction may be accomplished by reducing at least one of the following: a. the average total daily amount of adrenocortical hormone; or b. the average total daily amount adrenocortical hormone minus the integrative measure of morning peak adrenocortical hormone. Preferably, such reduction also includes reducing at least one of the following: c. the level of adrenocortical hormone 4 hours to 8 hours after waking; d. the level of adrenocortical hormone in the period of time preceding bedtime; or e. the level of adrenocortical hormone below the onset of sleep threshold.

The invention discloses fingered citron folium mori and wolfberry tea and a preparation method thereof. The tea is characterized by comprising the following raw materials in parts by weight: 13-20 parts of folium mori, 10-20 parts of chayote leaves, 7-10 parts of green tea, 3-5 parts of wolfberries, and 4-6 parts of liquorice. The tea combines essences of the folium mori, the chayote leaves and the green tea, and also comprises the wolfberries and the liquorice, and thus the tea is scientific in compatibility of medicines. The tea has the good taste and the pleasant tea aroma, is easy to prepare, has no pollution, is a all natural product, and has effects of increasing immunity, regulating adrenocortical hormone, lowering blood sugar, resisting bacteria, lowering blood pressure, resisting tumors, resisting ageing, curing stomachache, and the like.

The object of the present invention is to provide an olfactory disturbance therapeutic agent that is effective in repairing or regenerating olfactory epithelium that suffered damages such as scratches and can be administered for a long time.The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment.

The present invention relates to novel peptides that are selective corticotropin releasing hormone receptor type 2 (CRHR2) agonists and compositions thereof for the treatment, amelioration or inhibition of cardiovascular conditions, including but not limited to heart failure. The novel peptide agonists preferably comprise modifications that include pegylated peptides. Furthermore, the present invention also relates to methods for the treatment and prevention of a disease or disorder related to CRHR2 activity.

The invention aims to provide an anti-dairy cow transport stress pharmaceutical composition, which comprises the following crude drugs in parts by weight: 80-100g of spina date seed, 25-30g of Poria cocos, 15-20g of polygala tenuifolia, 15-20g of rhizoma anemarrhenae, 20-30g of jasmine, 10-20g of Scutellaria baicalensis, 5-10g of ossa draconis and 10-20g of oyster. Through experimental studies, the composition provided by the invention is capable of effectively preventing the blood sugar concentration of dairy cows under the stress state from rising and restraining the rise of the concentration of adrenocortical hormone and the concentration of lactic dehydrogenase, so, hearts and livers are prevented from being damaged. The anti-dairy cow transport stress pharmaceutical composition is convenient to use, i.e., the anti-dairy cow transport stress pharmaceutical composition only needs to be blended into a feed in an amount converted from the weights of the dairy cows. The anti-dairy cow transport stress pharmaceutical composition is expected to be developed to become a novel anti-stress pharmaceutical preparation product used before the dairy cow is transported.

The invention discloses a medicine and food homologous composition for alcohol use disorder and an application thereof, belonging to the technical field of health food. The composition of the invention is composed of dendrobium, polygonatum and kudzu root. The composition of the invention has significant protective effect on alcoholic liver injury in mice, including improving the morphology and structure of liver cells, improving liver function and liver lipid metabolism. On the other hand, the composition of the present invention can improve depression and anxiety-like reactions after alcohol withdrawal, reduce the elevation of corticotropin-releasing hormone, corticotropin and corticosterone caused by alcohol withdrawal; inhibit alcohol withdrawal Causes a decrease in the monoamine transmitters dopamine and norepinephrine.